LINDSAY HUMES: Open Payments
NPI 1578746525 · NORTH LOGAN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489 in 24 payments from 8 companies in 2025. Trend: 2023 $1,874 · 2024 $720 · 2025 $489
Food & beverage: $489
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $181 |
| GENZYME CORPORATION | 5 | $93 |
| AstraZeneca Pharmaceuticals LP | 4 | $67 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Amgen Inc. | 2 | $33 |
| ABBVIE INC. | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
Products named: DUPIXENT, TEZSPIRE, TRELEGY ELLIPTA, FASENRA, QULIPTA, NP Thyroid 60, TAVNEOS.
Industry payments across UT — which companies pay providers there.
